

General Information

Name: Prof. Dr. med. Stephan Stilgenbauer
Date of Birth: 27.11.1966
Gender: Male
Address: Department of Internal Medicine III, Ulm University
Albert-Einstein-Allee 23, 89081 Ulm, Germany
Phone: +49 731 500 45521
E-Mail: stephan.stilgenbauer@uniklinik-ulm.de
Current Position: Deputy chairman (Leitender Oberarzt)
Department of Internal Medicine III, Ulm University
Children: 2

Academic Education

6/1994 Medical Licensing Examination
1987-1994 Medical School, Heidelberg University

Academic Degrees

10/2005 Associate Professor of Medicine (*ausserplanmässige Professur*)
10/2002 Postdoctoral Thesis (*Habilitation*), Internal Medicine, Ulm University,
Mentor: Prof. Hartmut Döhner
12/1994 Doctoral Thesis (*Dr. med.*), Medicine, Heidelberg University, Advisor:
Prof. Peter P. Nawroth

Professional Experience

Since 2003 Associate Professor and Attending Physician (*Oberarzt*) Department
of Internal Medicine III, Ulm University
Since 1999 Group leader of the CLL research laboratory and central reference
laboratory genetics of the GCLLSG
2004 Boards in Hematology and Medical Oncology
2002 Boards in Internal Medicine
1999-2002 Fellowship in Internal Medicine, Hematology, Oncology,
Rheumatology, Infectious Diseases; Department of Internal Medicine
III, Ulm University (Director: Prof. Dr. H. Döhner)
1996-1998 Postdoctoral laboratory research fellow at the Department
"Organization of complex genomes" of the Deutsche
Krebsforschungszentrum, Heidelberg, Germany (Head: Prof. P.
Lichter)
1994-1999 Residency in Internal Medicine, Hematology, Oncology,
Rheumatology; Department of Internal Medicine V, Heidelberg
University (Director: Prof. W. Hunstein, Prof. R. Haas, Prof. A. D. Ho)

Miscellaneous

Awards, Honors, Positions:

2012 Paul Martini Preis der Deutschen Gesellschaft für Innere Medizin
Since 2012 Chairman, Certificate of Competence in Lymphoma, European School
of Oncology
Since 2011 Speaker of the "Else Kröner Forschungskolleg Ulm", funded by the
Else Kröner Fresenius Stiftung

Since 2010	Module Director, Module 4 (Advanced/Integrated Therapies) Master Online Advanced Oncology Program, Ulm University
2008	Walther und Christine Richtzenhain Award of the German Cancer Research Center, Heidelberg
2006	Merckle Research Award, Ulm University
2002	Artur Pappenheim Award, German Society of Hematology and Oncology
2001	Franziska Kolb Foundation, Research Award, Ulm University

Publications

- Landau DA*, Tausch E* Taylor-Weiner AN*, Stewart, C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Cibulskis K, Mertens D, Sougnez C, Rosenberg M, Hess JM, Carter SL, Edelmann J, Kless S, Fink A, Fischer K, Gabriel S, Lander E, Nowak MA, Döhner H, Hallek M*, Neuberg D*, Getz G*, Stilgenbauer S*, Wu CJ*. Somatic mutations driving chronic lymphocytic leukemia and their evolution in disease progression and relapse. **Nature**, 2015;526(7574): 525-30. *Equal contribution
- Bhattacharya N, Reichenzeller M, Caudron-Herger M, Haebe S, Brady N, Diener S, Nothing M, Döhner H, Stilgenbauer S, Rippe K, Mertens D. Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6. **Int J Cancer**. 2015;136(1):65-73.
- Stilgenbauer S, Furman RR, Zent CS. Management of chronic lymphocytic leukemia. **Am Soc Clin Oncol Educ Book**. 2015;35:164–175.
- Mertens D, Stilgenbauer S. Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches? **J Clin Oncol**. 2014;32: 869–872.
- Woyach JA, Furman RR, Liu T-M, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH-H, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC. Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib. **N Engl J Med**. 2014;370: 2286–2294.
- Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Döhner H. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. **Blood**. 2014;123: 3247–3254.
- Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dillhuydy M-S, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer K-A, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions **N Engl J Med**. 2014;370: 1101–1110.
- Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia **N Engl J Med**. 2014;370: 997–1007.
- Jebaraj BM, Kienle D, Lechel A, Mertens D, Heuberger M, Ott G, Rosenwald A, Barth TF, Möller P, Zenz T, Döhner H, Stilgenbauer S. Telomere length in mantle cell lymphoma. **Blood**. 2013;121(7):1184-1187.
- Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S. TP53 mutation and survival in chronic lymphocytic leukemia. **J Clin Oncol**. 2010;28:4473–4479.

Patents

“Superior efficacy of CD37 antibodies in CLL blood samples“ US, Europäische und Internationale Patentanmeldung (PCT EU 2010/1633)

„Predictive marker for cancer treatment“ (NOTCH1 Mutation und Wirksamkeit von CD20 Antikörpertherapie) EP12191323 (Europäische Anmeldung) Prioritätsdatum 05.11.2012